MA49863A - Anticorps dirigés contre la mort programmée 1 (pd -1) - Google Patents

Anticorps dirigés contre la mort programmée 1 (pd -1)

Info

Publication number
MA49863A
MA49863A MA049863A MA49863A MA49863A MA 49863 A MA49863 A MA 49863A MA 049863 A MA049863 A MA 049863A MA 49863 A MA49863 A MA 49863A MA 49863 A MA49863 A MA 49863A
Authority
MA
Morocco
Prior art keywords
directed against
antibodies directed
programmed death
against programmed
death
Prior art date
Application number
MA049863A
Other languages
English (en)
Inventor
Baochuan Huang
Marilyn Kehry
David J King
Original Assignee
Anaptysbio Inc
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc, Tesaro Inc filed Critical Anaptysbio Inc
Publication of MA49863A publication Critical patent/MA49863A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
MA049863A 2016-11-01 2017-11-01 Anticorps dirigés contre la mort programmée 1 (pd -1) MA49863A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662416128P 2016-11-01 2016-11-01
US201662427777P 2016-11-29 2016-11-29

Publications (1)

Publication Number Publication Date
MA49863A true MA49863A (fr) 2020-06-17

Family

ID=62075647

Family Applications (2)

Application Number Title Priority Date Filing Date
MA046724A MA46724A (fr) 2016-11-01 2017-11-01 Anticorps dirigés contre la mort programmée 1 (pd -1)
MA049863A MA49863A (fr) 2016-11-01 2017-11-01 Anticorps dirigés contre la mort programmée 1 (pd -1)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA046724A MA46724A (fr) 2016-11-01 2017-11-01 Anticorps dirigés contre la mort programmée 1 (pd -1)

Country Status (13)

Country Link
US (2) US11155624B2 (fr)
EP (2) EP3534950A4 (fr)
JP (1) JP2019533458A (fr)
KR (1) KR20190101364A (fr)
CN (1) CN110049777A (fr)
AU (1) AU2017354070A1 (fr)
BR (1) BR112019008859A2 (fr)
CA (1) CA3041684C (fr)
IL (2) IL266229A (fr)
MA (2) MA46724A (fr)
MX (1) MX2019005117A (fr)
SG (2) SG10201913306WA (fr)
WO (1) WO2018085468A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2992017T (lt) * 2013-05-02 2021-02-25 Anaptysbio, Inc. Antikūnai nukreipti prieš programuotos žūties baltymą-1 (pd-1)
SG10201913303XA (en) 2015-07-13 2020-03-30 Cytomx Therapeutics Inc Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
KR20190101364A (ko) 2016-11-01 2019-08-30 테사로, 인코포레이티드 예정 사멸-1(pd-1)에 대한 항체
DK3565844T3 (da) 2017-01-09 2023-05-01 Tesaro Inc Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
MX2020003760A (es) 2017-09-26 2020-07-29 Tesaro Inc Formulaciones de niraparib.
SG11202002862RA (en) 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
TW202024638A (zh) 2018-09-04 2020-07-01 美商泰沙羅公司 治療癌症之方法
WO2020072796A1 (fr) 2018-10-03 2020-04-09 Tesaro, Inc. Formes cristallines d'une base libre de niraparib
CN113166071A (zh) 2018-10-03 2021-07-23 特沙诺有限公司 尼拉帕利盐
KR20210102327A (ko) 2019-01-11 2021-08-19 일라이 릴리 앤드 캄파니 암 치료를 위한 tim-3 항체 및 다른 체크포인트 억제제와의 조합
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
EP4011918A4 (fr) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. Protéine bi-spécifique
IL293753A (en) 2019-12-18 2022-08-01 Tesaro Inc Biopharmaceutical preparations and related methods
US20230067202A1 (en) 2020-01-28 2023-03-02 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
EP4112049A1 (fr) * 2020-02-24 2023-01-04 Fukang (Shanghai) Health Technology Co., Ltd. Application anti-coronavirus de l'inhibiteur de la poly adp-ribose polymérase

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
CA2163427A1 (fr) 1993-05-21 1994-12-08 Stephen D. Lupton Genes hybrides bifonctionnels selectables, a base du gene de la cytosine desaminase (cd)
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
CA2414331C (fr) 2000-06-28 2011-11-29 Genetics Institute, Llc. Molecules pd-l2 : nouveaux ligands de pd-1 et utilisations de ceux-ci
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
EP1334659B1 (fr) 2000-11-15 2012-01-11 Ono Pharmaceutical Co., Ltd. Souris sans pd-1 et utilisation de celle-ci
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
EP2388590A1 (fr) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, récepteur pour B7-4 et utilisations associées
ATE524495T1 (de) 2001-07-31 2011-09-15 Ono Pharmaceutical Co Pd-1-spezifische substanz
CA2466279A1 (fr) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
EP3287144A1 (fr) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Compositions immunostimulantes
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
KR20050107399A (ko) 2003-01-23 2005-11-11 오노 야꾸힝 고교 가부시키가이샤 인간 ｐｄ-1에 대하여 특이성을 갖는 물질
PL2439273T3 (pl) 2005-05-09 2019-08-30 Ono Pharmaceutical Co., Ltd. Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
PL1907000T5 (pl) 2005-06-08 2020-11-16 Dana-Farber Cancer Institute Metody i kompozycje do leczenia infekcji przetrwałych
AU2006261127B2 (en) 2005-06-17 2012-03-15 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
EP1997887B1 (fr) 2006-03-03 2013-09-04 Ono Pharmaceutical Co., Ltd. Multimere de domaine extracellulaire d'une molecule fonctionnelle de surface cellulaire
NZ600281A (en) 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
EP2109608B1 (fr) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Indazoles à substitution amide utilisés comme inhibiteurs de la poly(adp-ribose)polymérase (parp)
WO2008103475A1 (fr) 2007-02-20 2008-08-28 Anaptysbio, Inc. Systèmes d'hypermutation somatique
MX2009010051A (es) * 2007-03-20 2009-10-12 Lilly Co Eli Anticuerpos anti-esclereostina.
EP2162472B1 (fr) 2007-05-30 2013-02-27 Postech Academy-Industry- Foundation Protéines de fusion d'immunoglobuline
EP2170959B1 (fr) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Anticorps dirigés contre le récepteur humain de mort programmée pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2009026472A1 (fr) 2007-08-21 2009-02-26 The General Hospital Corporation Procédés pour induire une tolérance
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
KR101653548B1 (ko) 2008-01-08 2016-09-02 머크 샤프 앤드 돔 리미티드 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
WO2010001617A1 (fr) 2008-07-04 2010-01-07 Ono Pharmaceutical Co., Ltd. Utilisation d’un marqueur d’efficacité destiné à optimiser l’efficacité thérapeutique d’un anticorps pd-1 anti-humain sur les cancers
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX2011002252A (es) 2008-08-25 2011-06-24 Amplimmune Inc Composiciones de antagonistas del pd-1 y metodos de uso.
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
EP2342228B1 (fr) 2008-09-12 2017-09-06 Oxford University Innovation Limited Anticorps spécifiques de pd-1 et leurs utilisations
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
WO2010063011A2 (fr) 2008-11-28 2010-06-03 Emory University Procédés pour le traitement d'infections et de tumeurs
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
PT2519543T (pt) 2009-12-29 2016-10-07 Emergent Product Dev Seattle Proteínas de ligação de heterodímero e suas utilizações
US20130202623A1 (en) 2010-02-16 2013-08-08 Nicolas Chomont Pd-1 modulation and uses thereof for modulating hiv replication
CA2791930A1 (fr) 2010-03-11 2011-09-15 Kerry Louise Tyson Anticorps pd-1
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2547781A4 (fr) 2010-03-17 2014-04-23 Anaptysbio Inc Procédé de production de produits de la transcription utilisant des sites cryptiques d'épissage
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
KR20130049196A (ko) 2010-08-05 2013-05-13 에프. 호프만-라 로슈 아게 항-mhc 항체 항-바이러스성 사이토카인 융합 단백질
US20130217656A1 (en) 2010-08-12 2013-08-22 Beth Israel Deaconess Medical Center Inc Methods and compositions for diagnosing and treating lupus
WO2012031122A2 (fr) 2010-09-03 2012-03-08 Immport Therapeutics, Inc. Méthodes et compositions pour le diagnostic et le traitement du cancer et des troubles auto-immuns
EP2638061B1 (fr) 2010-11-11 2015-04-22 The University of Hong Kong Variants solubles de pd-1, produits d'assemblage par fusion et leurs utilisations
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
TWI496886B (zh) 2011-06-24 2015-08-21 Taipei Veteran General Hospital 提升感染性與惡性疾病之治療之免疫反應
EP3939613A1 (fr) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Agent thérapeutique destiné à des maladies auto-immunes comprenant un agoniste de pd-1
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013169693A1 (fr) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Méthodes destinées à traiter le cancer à l'aide d'un polypeptide il-21 et d'un anticorps anti-pd-1
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20150079192A1 (en) 2012-05-21 2015-03-19 Marv Enterprises, LLC Treatment of cancer by manipulating the immune system
WO2013174997A1 (fr) 2012-05-25 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de malignités hématologiques réfractaires
WO2013181452A1 (fr) 2012-05-31 2013-12-05 Genentech, Inc. Procédés de traitement du cancer au moyen d'antagonistes liant l'axe pd-1 et d'antagonistes de vegf
LT2992017T (lt) * 2013-05-02 2021-02-25 Anaptysbio, Inc. Antikūnai nukreipti prieš programuotos žūties baltymą-1 (pd-1)
ME03527B (fr) * 2013-12-12 2020-04-20 Shanghai hengrui pharmaceutical co ltd Anticorps anti-pd-1, son fragment de liaison à l'antigène, et son application médicale
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
MX2016011993A (es) 2014-03-14 2016-12-09 Novartis Ag Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
CA2943167A1 (fr) 2014-03-24 2015-10-01 University Of Southampton Anticorps modifies contenant des domaines d'igg2 modifies conferant des proprietes agonistes ou antagonistes, et utilisation de ces derniers
JP6904707B2 (ja) 2014-06-19 2021-07-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化プログラム細胞死１遺伝子を持つ非ヒト動物
CA2957258C (fr) 2014-08-05 2023-11-07 MabQuest SA Reactifs immunologiques
CN107106687A (zh) 2014-10-03 2017-08-29 诺华股份有限公司 组合治疗
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
EP3233918A1 (fr) 2014-12-19 2017-10-25 Novartis AG Polythérapies
MA41218A (fr) 2014-12-19 2017-10-24 Advaxis Inc Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
US10239942B2 (en) 2014-12-22 2019-03-26 Pd-1 Acquisition Group, Llc Anti-PD-1 antibodies
JP6885867B2 (ja) 2014-12-31 2021-06-16 チェックメイト ファーマシューティカルズ， インコーポレイテッド 組合せ腫瘍免疫療法
CA2968141C (fr) 2015-01-16 2020-08-04 Hsing-Mao CHU Constructions moleculaires avec elements de ciblage et effecteur
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
FI3478286T3 (fi) 2016-06-29 2024-03-14 Tesaro Inc Menetelmiä munasarjasyövän hoitamiseksi
KR20190101364A (ko) 2016-11-01 2019-08-30 테사로, 인코포레이티드 예정 사멸-1(pd-1)에 대한 항체
DK3565844T3 (da) 2017-01-09 2023-05-01 Tesaro Inc Fremgangsmåder til behandling af cancer med anti-PD-1-antistoffer
JP7118073B2 (ja) 2017-01-09 2022-08-15 テサロ， インコーポレイテッド 抗ｔｉｍ－３抗体を用いてがんを処置する方法
SG11202002862RA (en) * 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer

Also Published As

Publication number Publication date
MX2019005117A (es) 2019-10-21
CA3041684C (fr) 2023-09-26
WO2018085468A1 (fr) 2018-05-11
IL266229A (en) 2019-06-30
EP3534950A4 (fr) 2020-05-06
US20190256600A1 (en) 2019-08-22
EP3666794A1 (fr) 2020-06-17
CN110049777A (zh) 2019-07-23
US20220089739A1 (en) 2022-03-24
AU2017354070A1 (en) 2019-05-16
BR112019008859A2 (pt) 2019-07-09
SG10201913306WA (en) 2020-02-27
IL280766A (en) 2021-04-29
KR20190101364A (ko) 2019-08-30
US11155624B2 (en) 2021-10-26
MA46724A (fr) 2021-04-21
SG11201903835WA (en) 2019-05-30
CA3041684A1 (fr) 2018-05-11
EP3534950A1 (fr) 2019-09-11
JP2019533458A (ja) 2019-11-21

Similar Documents

Publication Publication Date Title
MA46724A (fr) Anticorps dirigés contre la mort programmée 1 (pd -1)
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA47694A (fr) Anticorps anti-tigit
MA46057A (fr) Anticorps anti-ctla4
MA49034A (fr) Anticorps anti-lag3
CA200058S (fr) Collier
DK3411410T3 (da) Pd-1-antistoffer
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA45784A (fr) Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
IL265525A (en) New monoclonal antibodies against pd-1
MA47268A (fr) Anticorps anti-gpc3
MA53434A (fr) Anticorps anti-tigit
MA52884A (fr) Anticorps anti-il-11
MA50352A (fr) Anticorps multispécifiques
NO343600B1 (no) Innhegning for oppdrettsanlegg
DK3395801T3 (da) Arylazolforbindelse og skadedyrsbekæmpelsesmiddel
DK3475303T3 (da) Anti-cd19-antistofformuleringer
MA42843A (fr) Anticorps anti-cd115
MA51134A (fr) Anticorps anti-alpha-synucléine
MA44236A (fr) Anticorps anti-tgfbêta 2
DK3289871T3 (da) Børne- og kæledyrssikret giftfri gnaverfælde
DK3328993T3 (da) Haploide humane embryonale stamcellelinjer og somatiske cellelinjer og fremgangsmåder til fremstilling deraf
MA51135A (fr) Anticorps anti-alpha-synucléine
MA50654A (fr) Anticorps anti-pacap